Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M R Lassen

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Haemostasis|March 1, 1993
Fibrinogen and fibrin derivatives in traumatized patients: relation to injury severity and posttraumatic pulmonary dysfunctionJ V Sørensen, H P Jensen, H B Rahr, et al.
Seminars in Thrombosis and Hemostasis|October 1, 1991
Biologic tolerance of two different low molecular weight heparinsH M Christiansen, M R Lassen, L C Borris, et al.
Journal of Thrombosis and Haemostasis : JTH|January 22, 2010
Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2)B I Eriksson, A G G Turpie, M R Lassen, et al.
Journal of Thrombosis and Haemostasis : JTH|December 17, 2003
The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS studyB I Eriksson, G Agnelli, A T Cohen, et al.
Acta Orthopaedica Scandinavica|February 1, 1991
Prevention of thromboembolism in 190 hip arthroplasties. Comparison of LMW heparin and placeboM R Lassen, L C Borris, H M Christiansen, et al.
Thrombosis Research|May 20, 2008
Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatranG Agnelli, B I Eriksson, A T Cohen, et al.
The British Journal of Surgery|July 1, 1988
Heparin/dihydroergotamine for venous thrombosis prophylaxis: comparison of low-dose heparin and low molecular weight heparin in hip surgeryM R Lassen, L C Borris, H M Christiansen, et al.
Archives of Orthopaedic and Trauma Surgery|January 1, 1989
Prevention of thromboembolism in hip-fracture patients. Comparison of low-dose heparin and low-molecular-weight heparin combined with dihydroergotamineM R Lassen, L C Borris, H M Christiansen, et al.
International Angiology : a Journal of the International Union of Angiology|February 16, 2008
Major joint replacement. A model for antithrombotic drug development: from proof-of-concept to clinical useO E Dahl, L C Borris, D Bergqvist, et al.
Thrombosis Research|July 21, 1998
Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) StudyM R Lassen, L C Borris, B S Anderson, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Haemostasis|March 1, 1993
Fibrinogen and fibrin derivatives in traumatized patients: relation to injury severity and posttraumatic pulmonary dysfunctionJ V Sørensen, H P Jensen, H B Rahr, et al.
Seminars in Thrombosis and Hemostasis|October 1, 1991
Biologic tolerance of two different low molecular weight heparinsH M Christiansen, M R Lassen, L C Borris, et al.
Journal of Thrombosis and Haemostasis : JTH|January 22, 2010
Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2)B I Eriksson, A G G Turpie, M R Lassen, et al.
Journal of Thrombosis and Haemostasis : JTH|December 17, 2003
The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS studyB I Eriksson, G Agnelli, A T Cohen, et al.
Acta Orthopaedica Scandinavica|February 1, 1991
Prevention of thromboembolism in 190 hip arthroplasties. Comparison of LMW heparin and placeboM R Lassen, L C Borris, H M Christiansen, et al.
Thrombosis Research|May 20, 2008
Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatranG Agnelli, B I Eriksson, A T Cohen, et al.
The British Journal of Surgery|July 1, 1988
Heparin/dihydroergotamine for venous thrombosis prophylaxis: comparison of low-dose heparin and low molecular weight heparin in hip surgeryM R Lassen, L C Borris, H M Christiansen, et al.
Archives of Orthopaedic and Trauma Surgery|January 1, 1989
Prevention of thromboembolism in hip-fracture patients. Comparison of low-dose heparin and low-molecular-weight heparin combined with dihydroergotamineM R Lassen, L C Borris, H M Christiansen, et al.
International Angiology : a Journal of the International Union of Angiology|February 16, 2008
Major joint replacement. A model for antithrombotic drug development: from proof-of-concept to clinical useO E Dahl, L C Borris, D Bergqvist, et al.
Thrombosis Research|July 21, 1998
Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) StudyM R Lassen, L C Borris, B S Anderson, et al.
Pageof 7